eFlow Technology Partnering

Partnering for pharmaceutical companies

Optimized nebulizers for advanced aerosol therapies

PARI collaborates with pharmaceutical companies to develop and commercialize advanced aerosol therapies. These are based on the optimization of an efficient aerosol delivery platform called eFlow Technology to a drug formulation. Such eFlow Technology nebulizers are tailored to specific medications and the needs of the respective patient population.

PARI has extensive experience in the field of liquid aerosol delivery to the respiratory tract. More than 12 pharmaceutical companies already trust in eFlow Technology nebulizers and PARI’s expertise for the administration of their inhaled medication – from preclinical to commercial. Patients benefit from short nebulization times, ease-of-use, and clinically proven aerosol delivery.

Find out more about our technology, projects, services, and success stories!

Video on PARI’s eFlow Partnering

Watch this video to learn about PARI’s expertise in developing and manufacturing optimized nebulizers – the device part of innovative drug-device combinations for the treatment of respiratory diseases.

eFlow Technology nebulizers with digital therapy management: The PARI Connect eco-system.

Learn how it supports patients, directly and indirectly, through carefully considered device usability in combination with digital therapy management solutions.

Your innovative aerosol therapy – our drug-nebulizer expertise

All you need to know about our partnering approach for pharmaceutical companies.

Developing new drug-nebulizer combination products

Are you interested in the critical success factors and opportunities for bringing a new vibrating membrane nebulizer for a drug-device combination product to the market?